Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Age ≥ 18 years old~* Must be undergoing an open gynecologic procedure through a midline vertical incision with a gynecologic oncologist~Exclusion Criteria~* History of chronic pain~* History of opioid dependence~* Suspected or confirmed history of endometriosis~* History of fibromyalgia~* Suspected or confirmed interstitial cystitis or painful bladder syndrome~* History of or current opioid use prior to surgery~* Hypersensitivity to bupivacaine~* Severe hepatic or renal disease

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bupivacaine TAP Block (Type: ACTIVE_COMPARATOR): The first 15 patients enrolled will receive perioperative plain bupivacaine TAP blocks.
- Liposomal Bupivacaine TAP Block (Type: ACTIVE_COMPARATOR): After enrolling all 15 participants in the first arm, the next 15 patients enrolled will receive perioperative single-dose Liposomal Bupivacaine TAP blocks.
- Liposomal Bupivacaine TAP Block with Re-dosing (Type: ACTIVE_COMPARATOR): After enrolling all 30 patients in the first two arms, the final 15 patients enrolled will receive perioperative Liposomal Bupivacaine TAP blocks followed by redosing of the TAP blocks in 48-60 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).